EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype

Hanna Pikkujämsä iD, Karoliina Aro iD, Laura Bergqvist iD, Ralf Bützow iD, Maija Jakobsson, Joakim Dillner iD, Pekka Nieminen iD, Ilkka Kalliala iD, Belinda Nedjai iD, Karolina Louvanto iD

Acta Obstetricia et Gynecologica Scandinavica · 09.11.2026

DOI: 10.1111/aogs.70382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, online erschienen am 09.11.2026. Verfasst von Hanna Pikkujämsä und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Foundation Finland, Suomen Lääketieteen Säätiö, Suomalainen Lääkäriseura Duodecim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is an urgent need for biomarkers that can distinguish regressive from progressive cervical intraepithelial neoplasia (CIN) lesions to improve risk stratification in cervical cancer screening programs and avoid overtreatment. We aimed to evaluate the longitudinal performance of the S5 methylation classifier in predicting the clinical trajectory of untreated CIN grade 2 (CIN2) across different HPV genotype groups. Material and Methods This study included 122 women (aged 18–30) with histologically confirmed CIN2 enrolled in an active surveillance trial at Helsinki University Hospital, Finland (ISRCTN91953024). Patients were monitored every 6 months for up to 24 months with cytology, HPV genotyping, and colposcopy. S5 methylation levels (pyrosequencing) were compared between women who regressed to normal histology ( n = 89) and those who progressed to CIN3+ ( n = 22, including one microinvasive cancer) or had persistent CIN2 ( n = 11). Analysis was stratified based on baseline HPV genotypes.

Results

The baseline S5 classifier significantly predicted progression/persistence with an odds ratio (OR) of 1.15 (95%CI 1.05–1.25). When excluding HPV16/18, the S5 classifier demonstrated a similar, borderline predictive association (OR 1.19; 95%CI 1.00–1.41), whereas cytology and HPV genotyping did not. Longitudinal analysis showed that S5 methylation levels in progressors remained elevated throughout the 24‐month period, significantly predicting progression/persistence up to 18 months prior to histological diagnosis of progression.

Conclusions

In this active surveillance cohort, the S5 classifier showed potential as a prognostic triage biomarker for identifying progression in untreated CIN2, including cases with non‐HPV16/18 types. Our exploratory findings suggest that elevated methylation levels may precede histological progression by up to 18 months. As HPV16/18 prevalence declines, host‐viral methylation panels may offer improved risk stratification compared to standard triage, though larger prospective studies in vaccinated populations are needed to confirm these findings and establish clinical utility.

Schlagwörter

Stichwörter der Autor:innen

CINDNA methylationHPVHSILcervical intraepithelial neoplasiahigh‐grade squamous cell intraepithelial lesion

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Cancer Prevention Unit (CPU), Centre for Cancer Screening, Prevention and Early Diagnosis (CCSPED), Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.

ORCID-Profile: Hanna Pikkujämsä, Karoliina Aro, Laura Bergqvist, Ralf Bützow, Joakim Dillner, Pekka Nieminen, Ilkka Kalliala, Belinda Nedjai, Karolina Louvanto

Förderung

  • Cancer Foundation Finland
  • Suomen Lääketieteen Säätiö
  • Suomalainen Lääkäriseura Duodecim
  • Sigrid Juselius Foundation
  • Research Council of Finland
  • Syöpäsäätiö

Zitieren

APA

Pikkujämsä, H., Aro, K., Bergqvist, L., Bützow, R., Jakobsson, M., Dillner, J., Nieminen, P., Kalliala, I., Nedjai, B., & Louvanto, K. (2026). Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70382

Vancouver

Pikkujämsä H, Aro K, Bergqvist L, Bützow R, Jakobsson M, Dillner J, et al. Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70382

BibTeX
@article{Pikkujms2026,
  author = {Pikkujämsä, Hanna and Aro, Karoliina and Bergqvist, Laura and Bützow, Ralf and Jakobsson, Maija and Dillner, Joakim and Nieminen, Pekka and Kalliala, Ilkka and Nedjai, Belinda and Louvanto, Karolina},
  title = {Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  doi = {10.1111/aogs.70382}
}
Kostenlos starten →